Scancell Holdings (GB:SCLP) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Scancell Holdings plc has announced the MHRA’s approval to include an additional cohort in its ModiFY cancer trial, using its Modi-1 vaccine in conjunction with a combination of checkpoint inhibitors to treat untreated renal cell carcinoma patients. The expansion is supported by promising early data from the Modi-1 monotherapy, highlighting its safety and potential in improving treatment responses. This development is a significant step for Scancell, suggesting a potential paradigm shift in treating renal and other challenging cancers.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
